A nationwide, randomized, placebo-controlled trial revealed that daily supplementation with high-dose vitamin D or n-3 fatty acids for 5 years among initially healthy adults in the US did not reduce the incidence of cancer or the incidence of major cardiovascular events. The trial included 25,871 participants (5106 black, ages >/=50 years for men and >/=55 years for women). Marine n−3 (i.e. omega-3) fatty acids were supplemented at a dose of 1 g per day and vitamin D3 (cholecalciferol) was supplemented at a dose of 2000 IU per day. During a median follow-up of 5.3 years, cancer was diagnosed in 793 participants in the vitamin D group and 824 in the placebo group; hazard ratio (HR), 0.96. A major cardiovascular event occurred in 396 participants in the vitamin D group and 409 in the placebo group; HR, 0.97. A major cardiovascular event occurred in 386 participants in the n−3 group and in 419 in the placebo group; HR, 0.92 (HR for total myocardial infarction, 0.72 in the analyses of key secondary end points). Invasive cancer was diagnosed in 820 participants in the n−3 group and in 797 in the placebo group; HR, 1.03. No excess risks of bleeding, hypercalcemia or other serious adverse events were observed. The disappointing findings filled some knowledge gaps in a diverse U.S. cohort. Source: https://www.nejm.org/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.